TENORMIN Drug Patent Profile
✉ Email this page to a colleague
When do Tenormin patents expire, and what generic alternatives are available?
Tenormin is a drug marketed by Astrazeneca and Twi Pharms and is included in two NDAs.
The generic ingredient in TENORMIN is atenolol. There are thirty-four drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the atenolol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tenormin
A generic version of TENORMIN was approved as atenolol by TWI PHARMS on July 15th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TENORMIN?
- What are the global sales for TENORMIN?
- What is Average Wholesale Price for TENORMIN?
Summary for TENORMIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 163 |
| Clinical Trials: | 16 |
| Patent Applications: | 4,433 |
| Drug Prices: | Drug price information for TENORMIN |
| What excipients (inactive ingredients) are in TENORMIN? | TENORMIN excipients list |
| DailyMed Link: | TENORMIN at DailyMed |
Recent Clinical Trials for TENORMIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Tennessee Medical Center | Early Phase 1 |
| High Risk Obstetrical Consultants | Early Phase 1 |
| University of Tennessee Graduate School of Medicine | Early Phase 1 |
Pharmacology for TENORMIN
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for TENORMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | TENORMIN | atenolol | INJECTABLE;INJECTION | 019058-001 | Sep 13, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-004 | Apr 9, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TENORMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-004 | Apr 9, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TENORMIN
See the table below for patents covering TENORMIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Yugoslavia | 41070 | ⤷ Sign Up | |
| Switzerland | 547257 | VERFAHREN ZUR HERSTELLUNG VON ALKANOLAMINDERIVATEN. | ⤷ Sign Up |
| Switzerland | 556817 | VERFAHREN ZUR HERSTELLUNG VON ALKANOLAMINDERIVATEN. (1-(substd-phenoxy)-3-isopropylamino-2-propa - nols as beta-adrenergie blocking agents) | ⤷ Sign Up |
| Czechoslovakia | 153065 | ZPUSOB VYROBY FENOXYPROBANOLAMINU | ⤷ Sign Up |
| United Kingdom | 1285038 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
